GSK recalls anti-depressant after contamination in Cork
FDA issues warning after firms’s failure to address concerns since October inspection
GSK Ireland spokeswoman said last night that the company had triggered a product recall of the affected batches. Photograph: Getty
GlaxosmithKline has announced a product recall after the US Food and Drug Administration published a warning letter over contamination at the group’s Cork plant.
Some batches of a drug or drugs using the contaminated ingredient were later shipped, the FDA said, and GSK did not notify its customers about the lapse. The investigator also raised concerns about the suitability of the equipment used to manufacture the ingredients.
In the letter, dated March 18th, the FDA said GSK had not done enough to solve problems discovered at its Currabinny plant.
A GSK Ireland spokeswoman said last night that the company had triggered a product recall of the affected batches, although she was unable to say how much of the potentially contaminated drug had been shipped.
The FDA accuses GSK of failing to investigate fully “critical deviations” in quality after it first because aware of the contamination issue in January 2012.
The company has until April 9th to respond to the letter, outlining in detail the actions it proposes to correct the issue. – Additional reporting Reuters